Skip to content

Supplier News

Aurobindo launches generic of Suprax

Aurobindo Pharma Ltd. has received the first Abbreviated New Drug Application approval from the Food and Drug Administration for cefixime for oral suspension, USP, 100 mg/5 ml and 200 mg/5 ml. Cefixime for O.S. is bioequivalent and therapeutically equivalent to Suprax from Lupin Pharmaceuticals Inc.

Sandoz cleared to market Copaxone generic

Sandoz has received Food and Drug Administration approval for Glatopa, a treatment for multiple sclerosis (MS). The Novartis subsidiary said Thursday that its product is the first generic version of Teva’s Copaxone (glatiramer acetate injection) 20 mg/ml once-daily MS therapy.

NBTY bolsters senior management team

NBTY bolsters senior management team

NBTY Inc. has appointed four senior executives to its management team, who will be charged with spearheading growth initiatives for the nutritional supplement maker and marketer’s branded businesses. NBTY said Thursday that Andre Branch has joined the company as chief marketing officer.

Takeda U.S.A. names president

Ramona Sequeira has been appointed president of Takeda Pharmaceuticals U.S.A. Inc., a unit of Takeda Pharmaceutical Co. The company said this week that Sequeira will lead all business operations for the United States and report to Christophe Weber, president and chief executive officer of Takeda.

Glenmark to ship Lybrel generic

The Food and Drug Administration has granted Glenmark Generics Inc. USA final approval for levonorgestrel/ethinyl estradiol tablets (0.09 mg/0.02 mg), an oral contraceptive. Glenmark said Friday that its levonorgestrel/ethinyl estradiol tablets (0.09 mg/0.

Perrigo set to ship generic version of Exalgo

Perrigo Co. plc has received approval from the Food and Drug Administration for hydromorphone HCI extended-release tablets (8 mg, 12 mg and 16 mg), an opioid pain medication. Perrigo said that it expects to begin shipments of the product to pharmacies within the next few weeks.